



## BioPharmica Limited

7th May 2007  
BioPharmica [ASX:BPH] ASX Release

### BioPharmica Limited Joint Venture Patents as at 7 May 2007

BioPharmica Ltd has developed an extended patent portfolio around HLS5 as a target and its use in a variety of diseases. The detail is set out in the table below.

Application Number	Country	Type	Title	Filing Date	Applicant/Assignee Name
15063/01 (784629)	Australia	National Phase Entry	Tumour Suppressor Factor	24/11/2000	The University of Western Australia
00977327.6	European	National Phase Entry	Tumour Suppressor Factor	24/11/2000	The University of Western Australia
10/130971	USA	National Phase Entry	Tumour Suppressor Factor	24/11/2000	The University of Western Australia
PCT/AU2006/001470	International	PCT	Sumoylation Control Agent and Uses Thereof	07/10/2005	Biopharmica Ltd
PCT/AU2007/000459	International	PCT	Transcription Factor Modulator	07/04/2006	Biopharmica Ltd
PCT/AU2007/000399	International	PCT	Agent for the Treatment of Hormone-Dependent Disorders & Uses Thereof	28/03/2006	Biopharmica Ltd

#### For more information contact:

Dr Jenny Tollet  
Commercialisation Manager  
Tel: +61 8 9328 8366  
[jenny@biopharmica.com.au](mailto:jenny@biopharmica.com.au)

Yours Faithfully,

David Breeze  
Chairman